Semax Dosing Protocol — Russian Research, Intranasal vs Subcutaneous, and 10mg Vial Math

Semax is the most-studied synthetic neuropeptide in the Russian research record — developed in the 1980s at the Institute of Molecular Genetics (Russian Academy of Sciences), in clinical use in Russia since 1996, and indexed across hundreds of PubMed papers, most published in Russian-language journals. For UAE researchers running cognitive or neuroprotection-orientated protocols, Semax's dose record is unusually well-defined for a research peptide — but the intranasal vs subcutaneous distinction matters more than most peptides. This guide separates the routes and walks the 10 mg vial reconstitution math.

1. What Semax is — a synthetic ACTH(4-10) analogue

Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. The first four amino acids (Met-Glu-His-Phe) are the 4-7 fragment of adrenocorticotropic hormone (ACTH); the C-terminal extension (Pro-Gly-Pro) protects the peptide from rapid enzymatic cleavage. This molecular design is the central trick of the Semax story: native ACTH(4-10) has nootropic and neurotrophic activity but is destroyed in plasma within seconds. Semax extends the half-life enough to be a viable pharmacological tool — without the steroidogenic activity of full-length ACTH(1-39).

The Russian neuropeptide programme around Semax began in the 1980s under Ivan Ashmarin's group at Moscow State University. By 1996 the peptide had Russian regulatory approval for stroke, ophthalmic, and cognitive-disorder indications. The published dose record sits primarily in Russian-language clinical journals indexed on PubMed.

2. Intranasal Semax — the route the Russian research uses

Intranasal is the standard delivery route across the entire Russian clinical and research literature. The reasons are pharmacokinetic: intranasal Semax bypasses first-pass metabolism, achieves measurable CSF concentrations via the olfactory route, and reaches detectable hippocampal levels within ~15 minutes of administration in animal models. The clinical preparation in Russia is a 0.1% nasal solution — 1 mg/mL — supplied in dropper bottles.

Practical intranasal delivery: a calibrated dropper or nasal spray. A standard 50 microlitre drop of the 0.1% (1 mg/mL) solution delivers 50 mcg per drop. The typical Russian-clinical regimen is 2-3 drops per nostril, twice daily, totalling 400-600 mcg/day.

3. Subcutaneous Semax — when the research literature uses SC

Subcutaneous Semax is used in some research protocols where systemic exposure is preferred over the intranasal route's CSF-targeted profile. The published SC dose range overlaps with intranasal at the lower end and extends slightly higher:

• Standard research SC dose: 0.25-1 mg/day, single injection or divided.
• Extended-protocol SC: Up to 2 mg/day in some Russian preclinical animal-to-human-scaled protocols.
• Bioavailability advantage: SC has higher systemic exposure than intranasal, but lower CNS-targeted concentration per mg dosed.

Researchers running cognitive or BDNF-orientated work usually choose intranasal for the CNS-targeting advantage. Researchers running peripheral or systemic-effect protocols (the peptide has documented effects on autonomic regulation in animal models) often use SC for cleaner systemic dose-response.

4. The 10 mg vial — reconstitution math

REVIVE LAB UAE stocks Semax in 10 mg lyophilised vials. The reconstitution decision depends on intended delivery route:

5. The BDNF / NGF mechanism

The mechanistic story for Semax's cognitive and neuroprotective effects centres on rapid neurotrophic factor induction. Published research (Dolotov et al., Medvedeva et al., and others) shows that intranasal Semax upregulates BDNF and NGF mRNA in the hippocampus and frontal cortex within 90 minutes of administration, peaking around 3 hours post-dose. The effect lasts roughly 24 hours.

That rapid BDNF upregulation is the leading explanation for the cognitive and recovery effects observed in stroke and rehabilitation contexts — BDNF is the central regulator of synaptic plasticity, neuronal survival, and post-injury repair signalling. Secondary mechanisms documented in the literature include serotonergic and dopaminergic modulation, antioxidant gene expression, and reduced neuroinflammatory cytokine signalling.

6. Stability and storage — Semax in the UAE context

Lyophilised Semax is highly stable at refrigeration temperature, with 24+ month shelf life at 2-8 °C. Tolerant of room-temperature transport windows of up to 48 hours — the entire REVIVE LAB UAE same-day delivery envelope falls well within that. Once reconstituted:

• Refrigerated (2-8 °C): 28 days typical stability for reconstituted Semax in bac water.
• Room temperature: Not recommended for >24 hours — bac water provides bacteriostatic protection, not peptide thermal stability.
• Freezer (-20 °C): Single-thaw only. Repeated freeze-thaw cycles damage peptide integrity.
• UAE summer specific: Ambient 45 °C+ from June-September is well above the safe handling envelope for reconstituted peptide. Transfer to refrigeration immediately on arrival.

For the full UAE thermal-stability decision matrix, see UAE peptide cold-chain shipping.

7. Semax in the cognitive stack context

Researchers building cognitive-orientated peptide stacks often pair Semax with one or more of: Selank (the GABAergic anxiolytic counterpart from the same Russian programme), NAD+ precursors (for mitochondrial-derived cognitive support), and Tesamorelin (for the Baker 2012 hippocampal-volume effect in older adults). The mechanistic case for combining is that each peptide hits a different pathway: BDNF / NGF (Semax), GABA-A modulation (Selank), mitochondrial coenzyme function (NAD+), and IGF-1 / GH axis (Tesamorelin). There is no published RCT for the combined stack, but each component has independent dose data.

8. The endpoints Semax research has and hasn't demonstrated

• Yes: BDNF/NGF upregulation in animal models — robust and replicated.
• Yes: Stroke neuroprotection in Russian clinical trials — multi-centre RCT evidence published in Russian-language neurology journals.
• Limited: Large-sample Western RCT data on cognitive endpoints in healthy adults — the bulk of cognitive-support claims comes from Russian-language clinical experience.
• Unknown: Long-term (>6 months) administration effects, interactions with antidepressants or stimulants, pharmacodynamics at supraphysiological doses.

9. UAE supply context

UAE researchers ordering Semax face a quality-control challenge: the heptapeptide is a relatively complex synthetic and purity matters for reproducible research outcomes. REVIVE LAB UAE supplies HPLC-verified Semax in the 10 mg vial format with batch-level certificate of analysis. Same-day Dubai dispatch on orders before 3 PM, 24-hour delivery across the seven emirates. Order via Semax UAE.

10. The summary

• Semax is a synthetic ACTH(4-10) analogue (Met-Glu-His-Phe-Pro-Gly-Pro) — heptapeptide with documented BDNF/NGF upregulation.
• Intranasal is the standard Russian-research route: 250-1000 mcg/day, divided 2-3 applications.
• Subcutaneous range: 0.25-1 mg/day.
• 10 mg + 10 mL bac water = 1 mg/mL — matches Russian 0.1% clinical solution (50 mcg per 50 µL drop).
• Refrigerate reconstituted vials at 2-8 °C, use within 28 days. UAE summer ambient demands immediate refrigeration.
• Available as Semax UAE via REVIVE LAB in HPLC-verified 10 mg vials with lot-level COA.